Baynes Roy D.
SEC insider (Form 3/4/5 filer). CIK 0001680739. Director at Aardvark Therapeutics, Inc. (AARD) and 4 other issuers. 56 reported Form 4/5 transactions since Sep 2024; latest on Aug 14, 2026. Located in SAN DIEGO, CA.
Companies Baynes Roy D. has filed insider reports for
- Aardvark Therapeutics, Inc. (AARD): Director
- Natera, Inc. (NTRA): Director
- Travere Therapeutics, Inc. (TVTX): Director
- Nurix Therapeutics, Inc. (NRIX): Director
- Eikon Therapeutics, Inc. (EIKN): Officer, Chief Medical Officer
Baynes Roy D.
CIK: 0001680739
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (56 total)
- Aug 14, 2026AARD
Aardvark Therapeutics, Inc.
AwardDirectStock Option (right to buy)
45K shares- - Jun 26, 2026NTRA
Natera, Inc.
AwardDirect75 shares- - Jun 26, 2026NTRA
Natera, Inc.
AwardDirect1.6K shares- - Jun 12, 2026TVTX
Travere Therapeutics, Inc.
ExerciseDirect4.5K shares at avg. $21.38$96K - Jun 12, 2026TVTX
Travere Therapeutics, Inc.
SaleDirect4.5K shares at avg. $50.00$225K - May 19, 2026TVTX
Travere Therapeutics, Inc.
AwardDirect4K shares- - May 15, 2026NRIX
Nurix Therapeutics, Inc.
AwardDirectDirector Stock Option (right to buy)
31.3K shares- - May 5, 2026TVTX
Travere Therapeutics, Inc.
SaleDirect4.5K shares at avg. $46.65$210K - May 5, 2026TVTX
Travere Therapeutics, Inc.
ExerciseDirect4.5K shares at avg. $18.27$82K - May 1, 2026TVTX
Travere Therapeutics, Inc.
SaleDirect9.8K shares at avg. $44.22$431K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 14, 2026 |  AARD Aardvark Therapeutics, Inc. | Award Stock Option (right to buy) | 44,964 | - | - | Direct |
| Jun 26, 2026 |  NTRA Natera, Inc. | Award | 75 | - | $0 | Direct |
| Jun 26, 2026 | NTRA Natera, Inc. | Award | 1,571 | - | $0 | Direct |
| Jun 12, 2026 |  TVTX Travere Therapeutics, Inc. | Exercise | 4,500 | $21.38 | $96,210 | Direct |
| Jun 12, 2026 | TVTX Travere Therapeutics, Inc. | Sale | 4,500 | $50.00 | $225,000 | Direct |
| May 19, 2026 | TVTX Travere Therapeutics, Inc. | Award | 4,000 | - | $0 | Direct |
| May 15, 2026 |  NRIX Nurix Therapeutics, Inc. | Award Director Stock Option (right to buy) | 31,250 | - | - | Direct |
| May 5, 2026 | TVTX Travere Therapeutics, Inc. | Sale | 4,500 | $46.65 | $209,925 | Direct |
| May 5, 2026 | TVTX Travere Therapeutics, Inc. | Exercise | 4,500 | $18.27 | $82,215 | Direct |
| May 1, 2026 | TVTX Travere Therapeutics, Inc. | Sale | 9,750 | $44.22 | $431,145 | Direct |
1-10 of 56 transactions